key: cord-0955998-mtcaoifb
authors: Lee, Dan Bi; Kim, Hyojin; Jeong, Ju Hwan; soon Jang, Ui; Chang, You Yeon; Roh, Seokbeom; Jeon, Hyunbum; Kim, Eun Jeong; Han, Su Yeon; Maeng, Jin Young; Magez, Stefan; Radwanska, Magdalena; Mun, Ji Young; Jun, Hyun Sik; Lee, Gyudo; Song, Min-Suk; Lee, Hye-Ra; Chung, Mi Sook; Baek, Yun Hee; Kim, Kyung Hyun
title: Mosaic receptor-binding domain nanoparticles induce protective immunity against SARS-CoV-2 challenges
date: 2022-02-18
journal: bioRxiv
DOI: 10.1101/2022.02.18.480994
sha: 56dfa6837a87c73ab43529bd41914248532e01ca
doc_id: 955998
cord_uid: mtcaoifb

Recurrent spillovers of α- and β-coronaviruses (CoV) such as acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome (MERS)-CoV, SARS-CoV-2, and possibly human CoV (NL63, 229E, OC43, and HKU1) have caused serious morbidity and mortality worldwide. Six receptor binding domains (RBDs) derived from α- and β-CoV that are considered to have originated from animals and cross-infected humans were linked to proliferating cell nuclear antigen (PCNA) heterotrimeric subunits, PCNA1, PCNA2, and PCNA3. These were used to form a scaffold-based mosaic multivalent antigen, 6RBD-np. Electron microscopic and atomic force microscopic images show a ring-shaped disk with six protruding RBDs, like jewels in a crown, with a size of 40 nm. Prime-boost immunizations with 6RBD-np in BALB/c mice elicited strong, dose-dependent antibody responses. In human angiotensin converting enzyme 2-transgenic mice, the same immunization induced full-protection against SARS-CoV-2 wild type and Delta challenges, resulting in a 100% survival rate. The mosaic 6RBD-np provides a potential platform for developing a pan-CoV vaccine against newly emerging SARS-CoV-2 variants and future CoV spillovers. Significance Despite the arsenal of COVID-19 vaccines, hospitalization and mortality associated with SARS-CoV-2 (acute respiratory syndrome coronavirus 2) variants remain high. There is an urgent need to develop next-generation COVID vaccines that provide broad protection against diseases by current and newly emerging SARS-CoV-2 variants. In this study, six receptor binding domains (RBDs) derived from α- and β-CoV were linked to proliferating cell nuclear antigen (PCNA) heterotrimeric scaffolds. They assemble to create a stable mosaic multivalent nanoparticle, 6RBD-np, displaying a ring-shaped disk with six protruding antigens. The prime-boost immunization in BALB/c and human angiotensin converting enzyme 2-transgenic mice with the 6RBD-np elicited strong, dose-dependent antibody responses and induced full-protection against both the SARS-CoV-2 wild type (WT) and Delta challenges. This study provides proof-of-concept that the mosaic 6RBD-np induces 100% protection against SARS-CoV-2 WT and Delta. It provides the potential of co-displaying heterologous antigens for novel vaccine designs, which can be deployed countering future pandemics.

of confirmed cases and severe illness 19 . With the repeated booster vaccination, however, it has been 81 suggested that immunological imprinting directed toward strain-specific antigens may lead to over-82 specialization of immunodominant B cells with limited breadth and a low activation of cross-reactive 83 B cell with broad protection 26 . In this context, co-display of heterologous RBDs on nanoparticles has 84 proven that the mosaic nanoparticles provide an avidity advantage to cross-reactive B cells, eliciting 85 broader Ab responses than those induced by a mixture or cocktail of nanoparticles in animal 86 experiments 26-28 . These innovative platforms prepared by designed scaffold, sortase A or Spy-tag-87 mediated fusion chemistry clearly induced high immunogenicity against RBDs and cross-reactive B 88 cells with sufficient breadth. However, most of the platforms reported so far have significant drawbacks 89 associated with employing a mixture of antigen-fused tags or scaffolds to assemble mosaic 90 nanoparticles. In these cases, co-display of heterologous RBDs is challenging in mass production, due 91 to the difficulty to achieve a uniform distribution of antigens on nanoparticles. 92 In this study, we embraced an approach that a novel self-assembling scaffold, proliferating cell 93 nuclear antigen (PCNA), can form mosaic nanoparticles incorporating heterotypic antigens in uniform 94 distribution. PCNA is a ring-shaped protein that encircles DNA as a processivity factor 29-31 . Most 95 archaea encode a homotrimeric PCNA from bacteria to higher eukaryotes, including human, whereas 96 and 355.7 kDa (±3.6%), respectively ( Fig. 1C and Extended Data Fig. 3) . The 6RBD-np was further 133 examined using atomic force microscopy (AFM) and transmission electron microscopy (TEM) to 134 characterize its assembly, size, and morphology. A ring-shaped scaffold structure with protruding 135 RBD-SD1 antigens was clearly observed, with an overall size of 40 nm (Figs. 1D and 1E) . 136 Antigenic characterization of mosaic 6RBD-np 137 The purified components, S-PCNA1, M-PCNA2 and H-PCNA3, were subjected to Western blot with 138 anti-His-tag monoclonal Ab (mAb) (Abcam, Cambridge, UK) and anti-SARS-CoV-2 spike polyclonal 139 Ab (pAb) (Sino Biological, China). All the antigens were detected by the anti-His-tag mAb and by the 140 SARS-CoV-2 pAb, except for the H-PCNA3 ( Fig. 2A) . The H-PCNA3 was not detected by the anti-141 SARS-CoV-2 spike Ab, whereas the 6RBD-np and H-PCNA3 were identified by the anti-HKU1 spike 142 mAb. The results clearly demonstrate that the engineered RBD antigens are present in the purified 143 antigens, including the 6RBD-np. It is notable that the number of protein bands on Western blot 144 detected by the anti-His-tag, anti-SARS-CoV-2, and anti-HKU1 Abs were 3, 2, and 1, respectively, 145 strongly suggesting that the mosaic 6RBD-np indeed contain 6 RBD antigens in uniform distribution 146 on nanoparticles. 147 Stability of mosaic 6RBD-np 148 The stability of the component proteins and 6RBD-np was monitored at −80℃, 4℃, 25℃, and 37℃ 149 over a 28-day storage period, using SDS-PAGE and SEC. They were stable and resistant to degradation 150 at −80℃ over 28 days ( Fig. 2B and Extended Data Fig. 4 ). Incubation at 4℃ also showed excellent 151 stability, and partial degradation started at 21 or 28 days in S-PCNA1 only. In contrast, severe 152 degradation was observed at 25℃ after 4 days of incubation. Significant degradation started in all the 153 antigens at 37℃ after 1 day of incubation. The stability for these antigens was also examined using 154 SEC after 30 days ( Fig. 2C and Extended Data Fig. 5 ). The 6RBD-np and H-PCNA3 were found to be 155 stable for more than 30 days at 4℃, at which other components S-PCNA1 and M-PCNA2 are less 8 stable. Therefore, the results suggest that the mosaic nanoparticle, 6RBD-np, is likely to be equally or 157 more stable upon assembly than the components, representing a stable mosaic multivalent nanoparticle. 158 In vivo immune response against antigens 159 Immunogenicity of the antigens was evaluated in BALB/c mice who received intramuscular prime-160 boost immunizations with a 3-week interval. Blood samples were collected at three time points: two 161 weeks post-prime and two and four weeks post-boost (Fig. 3A) . The mice were divided into six groups 162 of RBD-SD1 of SARS-CoV-2, spike ectodomain with two proline substitutions (S-2P) of SARS-CoV-163 2, S-PCNA1, and 6RBD-np (n=10), including the naïve and PCNA control (n=5) groups. In RBD-164 based ELISA assays, both the S-PCNA1 and 6RBD-np groups showed the highest Ab titers after the 165 boost, followed by the RBD-SD1 and S-2P groups (Fig. 3A , middle panel). The S-PCNA1 group, 166 containing the SARS-CoV-2 and SARS-CoV RBD-SD1 immunogens, is considered to receive half 167 the amount of the SARS-CoV-2 RBD-SD1, compared to the RBD-SD1 group. Likewise, the 6RBD-168 np mice are estimated to receive a sixth of the amount of the SARS-CoV-2 RBD-SD1. In this context, 169 the results strongly suggest that both the 6RBD-np and S-PCNA1 groups showed significant and 170 robust Ab responses, compared with the others. When the Ab responses in the post-boost sera were 171 further compared with respect to dosage (15 μg vs 5 μg) and adjuvants (SAS, AddaVax and CpG-172 ODN), the 15 μg (3) 6RBD-np group achieved the highest Ab response (Fig. 3A , lower panel). The 173 adjuvants in this study enhanced the immune responses, but no significant difference was observed 174 among the adjuvant groups. Therefore, our results demonstrate that the 6RBD-np induces strong 175 antigen-specific Ab responses in mice by prime-boost immunizations. 176 We then assessed antigen-specific Ab titers in the mice sera, using purified recombinant RBD-177 SD1s of SARS-CoV-2 (WT and VAR), SARS-CoV, and hCoV HKU1. The groups of S-PCNA1 and 178 6RBD-np showed distinctly high Ab titers against SARS-CoV-2 (WT and VAR) and SARS-CoV 179 RBD-SD1s, whereas only the 6RBD-np group displayed high Ab titers against the HKU1 RBD-SD1 180 (Fig. 3B) . The results also suggest that the 6RBD-np displays mosaic heterologous RBD antigens. 181 Further, neutralizing activities of the mice sera against pseudoviruses encoding spike of SARS-CoV 182 and spike mutants of SARS-CoV-2 including D614G (Wuhan variant), L452R/T478K/D614G (Delta 183 variant), N532A, and E554A/N556A (SD1 variants) were determined. The results show that the 6RBD-184 np group neutralized the entry of pseudoviruses, expressing SARS-CoV spike or SARS-CoV-2 spikes 185 containing D614G, Delta or SD1 mutations, with high efficacy (Fig. 3C ). The neutralization of the 186 6RBD-np group was lower than the RBD-SD1 group against the Delta spike. Nevertheless, our data 187 strongly suggest that the nAbs in the 6RBD-np group neutralized cell entry of pseudoviruses, 188 irrespective of RBD and SD1 mutations and irrespective of SARS-CoV and SARS-CoV-2 spikes used 189 in this study. have been identified globally [23] [24] [25] 43 , and the Omicron variant, harboring 37 amino acid changes to the 233 spike protein, has substantially increased ability to evade immunity from vaccination or prior 234 infection [43] [44] [45] . As the current vaccines are mostly directed toward the viral spike protein, specifically in 235 receptor interaction, the variants have raised a global concern over waning immunity and a global threat 236 to public health 38 . Nevertheless, nAbs against multiple variants are currently accepted as a correlate of 237 protection 12,37 , and the RBD indeed accounts for more than 90% of the neutralizing activity in sera 238 from COVID-19 convalescent and vaccinated individuals 9-12 . RBD monomer, dimer and trimer 239 antigens elicited potent Ab responses 9,10,13 , while highly ordered and repetitive structures of RBDs 240 mimicked the organization and density of antigens on natural virions, to be of great advantage in 241 promoting protective immunity 17,46,47 . Self-assembling multivalent RBD or spike nanoparticles using Molecular self-assembly of current mosaic nanoparticles is commonly achieved by mixing 253 heterologous antigen-fused tags or scaffolds, However, a formulation of mosaic nanoparticles with a 254 uniform distribution of heterotypic antigens cannot be ensured, and quality assurance in mass 255 production will be more challenging in human trials. In this study, six heterologous RBD-SD1s are 256 fused to the N-and C-termini of PCNA1, 2, and 3, which are assembled in a defined order to form a 257 nanoparticle, driven by specific interactions of the heterotrimeric subunits 29,30 . Each PCNA subunit 258 confers two heterologous RBD-SD1 antigens at the N-and C-termini, and the assembled heterotrimer 259 can present up to six heterologous RBD-SD1s. The 6RBD-np characterized by SEC-MALS, TEM and 12 AFM has a molecular weight of 355 kDa with an overall size of 40 nm, which appears to be a ring- 261 shaped disk with six protruding RBD-SD1s, like jewels in a crown ( Fig. 1D & 1E ). Antigenic 262 characterization by Western blot using His-tag mAb, SARS-CoV-2 pAb, and HKU1 Ab reveals that 263 six heterologous RBD antigens are uniformly distributed on the 6RBD-np nanoparticle. 264 Efficient cellular uptake, entry into, and retention at lymph nodes of antigens are crucial for 265 improved immunogenicity and protection, which is influenced by the size of antigen nanoparticle 266 platforms 48,49 . Self-assembled protein nanoparticles are defined as a material that is deliberately 267 manipulated to have dimensions between 1 to 100 nm or up to 1,000 nm if they exhibit physical, The 6RBD-np (40 μL drop at 10 ng/mL) was deposited on a freshly cleaved mica surface and 366 incubated for 15 min. To remove weakly bound protein residues and salts, the sample was washed 367 with distilled water ten times and dried by N2 gas. The prepared sample was mounted on AFM scanner. 368 The AFM data of 6RBD-np were acquired by soft tapping mode under ambient conditions using . To obtain sera, mice were bled two weeks after prime and boost immunizations. Blood was 389 collected via facial vein puncture in 1.5 mL Eppendorf tubes, which was stored at room temperature 390 for 30 min to allow for coagulation. Serum was separated by centrifugation at 2,000 g for 15 min. 391 Complement factors and pathogens in the serum were heat-inactivated at 56°C for 60 min, which were 392 centrifuged and stored at −80°C until use. 

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike 513

Receptor-Binding Domain by Structure-Guided High-Resolution Serology

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective 516 immunity

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, 518 and SARS

A recombinant receptor-binding domain in trimeric form generates protective 520 immunity against SARS-CoV-2 infection in nonhuman primates. Innovation (N Y) 2, 100140

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein

Protein-based antigen presentation platforms for nanoparticle 595 vaccines

Vaccine delivery: a matter of size, geometry, kinetics and 597 molecular patterns

MD: US Department of Health & Services, H. Drug Products, Including 599 Biological Products, That Contain Nanomaterials-Guidance for Industry

Regulation of IgG antibody responses by epitope density and CD21-601 mediated costimulation

Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus

H-PCNA3, and 6RBD-633 np, using anti-His-tag mAb, anti-SARS-CoV-2 spike pAb, and anti-MERS-CoV spike mAb. The S-634 PCNA1 and M-PCNA2 are detected by the SARS-CoV-2 pAb

are detected by the anti-HKU1 spike mAb. (B & C) Time-course experiments 636 of 6RBD-np monitored at −80℃, 4℃, 25℃, and 37℃ over a 28-day storage period using SDS-PAGE 637 and SEC. (B) The left lane, molecular weight markers

C) Elution profiles of 6RBD-np, obtained at day 0 (continuous line) and 30 at 4℃ 639 (dotted) and 37℃ (dashed), after size exclusion chromatography on

Immunogenicity of antigens in BALB/c mice. (A) Prime-boost immunization study design 641 with BALB/c mice (upper panel). The mice were immunized in six groups. Blood was collected two 642 weeks after the prime and boost immunizations and 26 days after the boost

RBD-SD1 of SARS-CoV-2, S-2P of SARS-CoV-2, S-PCNA1, and 6RBD-np, represented as 645 molecular structures of the respective immunogens with arrows (middle panel)

6RBD-np group shows the highest Ab response, compared to other groups. (B) Post-boost

Ab titers against the purified RBD-SD1s of the SARS-CoV-2 (WT and VAR)

Pseudoviruses 653 expressing SARS-CoV-2 spike WT, Delta, and SD1 mutants were inoculated with different sera from 654 the naïve and PCNA controls, RBD-SD1 and S-2P of SARS-CoV-2, S-PCNA1, and 6RBD-np groups, 655 which were serially diluted prior to transduction on HEK293T-hACE2 cells. Neutralization was 656 performed twice and a representative is shown

RBD-SD1 amplification Primer sequences

Their elution profiles 697 from the final size exclusion chromatography steps, using Superdex 200 increase 10/300 GL, and SDS-698 PAGE results are shown on the right. The purified S-PCNA1, M-PCNA2 and H-PCNA3 have 699 molecular weights in the range of 100−120 kDa, approximately consistent with their expected 700 molecular weights of 97, 101, 120 kDa, respectively. (B) The shifts in elution profiles after assembly 701 of 6RBD-np are shown for comparison, using size exclusion chromatography on Superdex 200 702 increase 10/300 GL. The purified S-PCNA1 and M-PCNA2 were mixed in a 1.2:1 molar ratio

Extended Data Fig. 2. Characterization of 6RBD-np. The elution profile of 6RBD-np from the final 705 size exclusion chromatography step

Extended Data Fig. 3. Characterization of 6RBD-np. The purified S-PCNA1, M-PCNA2 and H-708 PCNA3 are characterized using SEC-MALS to show molecular weights of 154

Extended Data Fig. 4. Stability of the 6RBD-np. Time-course experiments of S-PCNA1, M-PCNA2, 711 and H-PCNA3 monitored at −80℃, 4℃, 25℃, and 37℃ over a 28-day storage period using SDS-712

The left lane, molecular weight marker

Extended Data Fig. 5. Stability of the 6RBD-np

PCNA3, obtained at day 0 (continuous line) and 30 at 4℃ (dotted) and 37℃ (dashed), after size 715 exclusion chromatography on Superdex

Representative images of H&E and IHC staining of lungs in mice infected 717 with the wild type or Delta variant. Hematoxylin and eosin (scale bar, 100 m) and immunohistochemistry (zoomed-in scale bar, 50 μm) staining of lung sections collected at 5 dpi for 719 different groups are shown against SARS-CoV-2 wild type (left panel) and Delta variant

SARS-CoV-2 nucleoprotein (N) was detected in lung sections for IHC analysis in zoomed-721 in images of the box shown in the hematoxylin-and-eosin images, and the remainder was 722 counterstained with hematoxylin. Arrows depicted in IHC staining indicate cells strongly detected by 723 SARS-CoV-2 N protein specific antibody